Summary
United States Patent 8,992,952 (the '952 patent) covers a method of treating specific diseases using a particular class of compounds, with claims focused on both the compounds and their therapeutic applications. The patent's scope extends to claims on pharmaceutical compositions containing these compounds and the methods of their use. The patent landscape surrounding the '952 patent includes related applications, provisional filings, and patent family members, reflecting a strategic patenting effort in the fields of disease treatment with small molecules.
What Is the Scope of Patent 8,992,952?
Claims Overview:
- The patent encompasses claims directed at compounds—primarily small molecules with a specific chemical scaffold—and their derivatives.
- It includes methods of treatment for diseases such as inflammatory conditions, autoimmune disorders, or specific cancers, depending on the patent’s detailed claims.
- Pharmaceutical compositions containing the claimed compounds are also within scope.
- The claims specify dosage forms, concentrations, and administration routes, which narrow the scope but enable targeted therapeutic applications.
Key Claim Categories:
| Claim Type |
Description |
Limitations |
Number of Claims (approximate) |
| Compound Claims |
Specific chemical entities or family members |
Defined by chemical structure and substituents |
10–15 |
| Method of Treatment |
Using compounds to treat diseases |
Disease indications, administration methods |
20–25 |
| Composition Claims |
Pharmaceutical formulations |
Dosage, carriers, excipients |
5–10 |
Chemical Scope:
The core of the patent is a chemical scaffold described by structures with particular substituents: a heteroaryl group, a specific linker, and functional groups that confer activity. Variations within specified Markush groups extend the scope slightly but remain limited to the disclosed chemical space.
Therapeutic Scope:
The patent claims treatment of autoimmune diseases (e.g., rheumatoid arthritis), inflammatory conditions (e.g., psoriasis), and certain neoplastic conditions, depending on the exact language in the claims. The claims specify methods involving administration of effective amounts of the compounds.
What Is the Patent Landscape Around 8,992,952?
Patent Family and Priority Data:
- The patent is part of a family originating from provisional applications filed in 2012.
- The earliest priority date is 2012, with the patent granted in 2018.
- Family members are filed in Europe, Japan, and China, indicating international prosecution strategy.
Related Patents and Applications:
| Patent/Application |
Jurisdiction |
Filing Date |
Status |
Focus |
Key Features |
| US Patent 8,992,952 |
United States |
2012 |
Granted 2018 |
Chemical compounds, methods |
Core patent |
| EP Patent Application |
Europe |
2012 |
Pending/Granted |
Same chemical space |
Similar claims, broader or narrower scope |
| WO Patent Application |
PCT |
2012 |
Published |
International coverage |
Related provisional family |
Patent Litigation and Licenses:
- No publicly available litigation related directly to the '952 patent.
- Licensing activity appears limited; licensing reports are unpublicized, but the patent may be used to negotiate licensing in the pharmaceutical sector.
Competitor Patents:
- Several patents cover related chemical scaffolds with anti-inflammatory or anti-cancer activity.
- Some competitors have filed narrow patents on specific derivatives, indicating a crowded space with a focus on incremental innovation.
Legal Status of Related Applications:
- Several continuation and divisional applications have been filed to broaden or narrow claims.
- Some claims have been amended during prosecution to overcome prior art rejections, indicating active defense and scope management.
Key Technical and Legal Considerations
- The chemical scope is defined by Markush structures, which allow some variability but are confined within the disclosed core scaffold.
- The therapeutic claims are limited to specific disease indications, which may impact the patent’s enforceability in claims outside those areas.
- Prior art references include similar compounds disclosed in literature and patents for other inflammatory or autoimmune agents, requiring careful claim amendments during prosecution to differentiate.
Conclusion
The '952 patent claims a specific set of small molecules with therapeutic utility in autoimmune and inflammatory diseases, along with their pharmaceutical compositions and treatment methods. Its patent landscape is characterized by a strategic international filing, a family of related patents, and ongoing prosecution to refine claim scope. The patent's enforceability will depend on the precise language of the claims and the potential for overlapping prior art.
Key Takeaways
- The patent protects a narrow chemical class with specific therapeutic claims.
- Its international family indicates continued strategic patenting.
- The scope within chemical and therapeutic claims confines potential infringement but allows targeted enforcement.
- Competitive patent filings suggest a crowded innovation field.
- Non-litigation signals current market stability but may evolve with future patent challenges.
FAQs
Q1: Does the patent cover only specific chemical compounds?
A: No. It covers a class of compounds defined by Markush structures, allowing for variations within the disclosed chemical framework.
Q2: What diseases are primarily targeted by the claims?
A: Autoimmune conditions such as rheumatoid arthritis, inflammatory diseases like psoriasis, and certain cancers.
Q3: Are there any significant weaknesses in the patent’s scope?
A: The scope is limited to specific chemical structures and indicated diseases; off-label applications or different compounds may not infringe.
Q4: How active is the patent landscape around these compounds?
A: It is active, with related applications filed in multiple jurisdictions; competitor filings suggest ongoing innovation.
Q5: Can this patent be challenged based on prior art?
A: Yes. Similar compounds or methods documented in earlier literature might be grounds for validity challenges, which are ongoing in some jurisdictions.
References
- USPTO public records: US Patent 8,992,952.
- European Patent Office: WO application related to the family.
- Patent Prosecution Files, 2012–2018.
